2型糖尿病の市場規模、シェア、成長分析：薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、地域別 - 産業予測、2024-2031年

2型糖尿病の世界市場規模は2022年に340億7,000万米ドルと評価され、2023年の368億7,000万米ドルから2031年には665億2,000万米ドルに達し、予測期間中（2024-2031年）のCAGRで7.72％の成長が予測されています。

NCBIによると、世界の糖尿病治療市場は、2014年の8,900万例から2022年には3億3,000万例に達すると予想され、2型糖尿病（T2D）の急増を主因として力強い成長を遂げています。この急増は、グルカゴン様ペプチド-1受容体作動薬であるTanzeumやTrulicity、Naグルコース共輸送体2阻害薬であるJardianceなどの革新的な治療薬の導入に代表される、医薬品の進歩の動機付けとなっています。こうした進歩にもかかわらず、利用可能な治療法を取り巻く患者の認知度が低いため、市場成長は課題に直面しています。逆に、効果的な糖尿病管理ソリューションが急務となっている発展途上地域では、大きなビジネスチャンスが見込まれています。糖尿病有病率の増加は、より充実した治療オプションへの需要をさらに強め、より適応性の高い医療ソリューションを可能にする技術の進歩につながっています。クラウドベースの企業システムの台頭や、接続されたデバイスやアプリの人気は、市場拡大を促進する極めて重要な動向です。しかし、機器の高コスト、低所得国での不十分な資金調達、伝統的な糖尿病管理手法への継続的な依存といった阻害要因が、予測期間を通じてこの分野の成長を妨げる可能性があります。全体として、医療が進化し続ける中、テクノロジーと革新的な薬物療法の統合は、世界的に高まる糖尿病治療の需要を満たす上で不可欠となります。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場のエコシステム
• 技術分析
• 規制情勢
• 特許分析
• PESTEL分析
• パイプライン分析
• 価格分析

2型糖尿病市場：薬剤クラス別

• 市場概要
• ジペプチジルペプチダーゼ-4阻害剤
• グルカゴン様ペプチド1受容体作動薬
• ビグアナイド
• ナトリウム-グルコース共輸送体2（SGLT2）阻害剤
• その他

2型糖尿病市場：投与経路別

• 市場概要
• 経口
• 非経口

2型糖尿病市場：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

2型糖尿病市場：エンドユーザー別

• 市場概要
• 在宅医療
• 病院・クリニック
• 学術・研究機関
• その他

2型糖尿病市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Merck & Co., Inc.
• Boehringer Ingelheim
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Medtronic
• B. Braun Melsungen AG
• Abbott Laboratories
• F. Hoffmann-La Roche
• Insulet Corporation

Global Type 2 Diabetes Market size was valued at USD 34.07 billion in 2022 and is poised to grow from USD 36.87 billion in 2023 to USD 66.52 billion by 2031, growing at a CAGR of 7.72% during the forecast period (2024-2031).

The global diabetes care market is experiencing robust growth, primarily driven by the alarming rise in type 2 diabetes (T2D) cases, which soared from 89 million in 2014 to an anticipated 330 million by 2022, according to NCBI. This surge has motivated pharmaceutical advances, exemplified by the introduction of innovative therapies such as glucagon-like peptide-1 receptor agonists Tanzeum and Trulicity, as well as the sodium glucose cotransporter 2 inhibitor Jardiance. Despite these advancements, market growth faces challenges due to low patient awareness surrounding available treatments. Conversely, substantial opportunities are projected in developing regions where there is a pressing need for effective diabetes management solutions. The increasing prevalence of diabetes has further intensified the demand for enhanced care options, leading to technological progress that allows for more adaptable healthcare solutions. The rise of cloud-based enterprise systems and the popularity of connected devices and apps are pivotal trends driving market expansion. However, impediments such as the high cost of devices, inadequate funding in lower-income nations, and the continued reliance on traditional diabetes management methods may hinder growth in this sector throughout the forecast period. Overall, as healthcare continues to evolve, the integration of technology and innovative drug therapies will be essential in meeting the escalating demand for diabetes care globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the global type 2 diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global type 2 diabetes Market Segmental Analysis

Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Distribution Channel, End User, and Region. Based on Drug Class, the market is segmented into Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Biguanides, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Based on End User, the market is segmented into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the global type 2 diabetes Market

The rapid advancement of artificial intelligence (AI) is emerging as a significant market driver for the global type 2 diabetes market, revolutionizing the diagnosis and management of this chronic condition. AI's ability to analyze vast amounts of health data through machine learning algorithms enables the development of predictive models that assess individual risk of developing diabetes and its complications. This shift towards precision medicine fosters more personalized and effective treatment strategies, replacing traditional management techniques with data-driven approaches. As healthcare systems increasingly adopt these AI-enhanced solutions, the demand for innovative products and services in the type 2 diabetes space is expected to surge, fueling market growth.

Restraints in the global type 2 diabetes Market

The global type 2 diabetes market faces significant restraint from the lack of reimbursement systems in underdeveloped nations, which often leads to treatment non-compliance among patients. In countries like China and India, individuals are burdened with out-of-pocket expenses for essential diabetes management tools such as continuous glucose monitoring (CGM) systems, insulin, and blood glucose monitors. This financial strain limits access to integrated digital diabetes management solutions, subsequently hindering their widespread adoption in these regions. As the disparity in healthcare funding persists, the growth potential of the type 2 diabetes market in emerging economies may be stifled, affecting overall market expansion.

Market Trends of the global type 2 diabetes Market

The global type 2 diabetes market is increasingly trending towards personalized medicine, driven by advancements in digital health technologies and genetic testing. This customized approach tailors treatment plans to the individual characteristics of patients-including their genetic makeup, lifestyle factors, and comorbidities-aiming to optimize therapeutic outcomes. As healthcare providers recognize the importance of personalized solutions, there is a growing emphasis on enhancing patient adherence and minimizing side effects. This shift not only reflects the evolving expectations of patients seeking more effective and convenient treatments but also indicates a significant opportunity for innovative companies to leverage technology in delivering bespoke care in the diabetes sector.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Regulatory Landscape
• Patent Analysis
• PESTEL Analysis
• Pipeline Analysis
• Pricing Analysis

Type 2 Diabetes Market, by Drug Class

• Market Overview
• Dipeptidyl Peptidase-4 Inhibitors
• Glucagon-like peptide 1 receptor agonists
• Biguanides
• Sodium-glucose cotransporter 2 (SGLT2) inhibitors
• Others

Type 2 Diabetes Market, by Route of Administration

• Market Overview
• Oral
• Parenteral

Type 2 Diabetes Market, by Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Type 2 Diabetes Market, by End User

• Market Overview
• Homecare Settings
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Type 2 Diabetes Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments